New treatments against inflammatory bowel disease (IBD) rarely make it to market due to a lack of reliable and predictive models for early drug screening. The models currently used, such as 2D in vitro models, organoids, and in vivo models suffer from significant drawbacks. These drawbacks include the failure to reproduce human physiology, interspecies differences, undesired complexity, and low throughput. Organ-on-a-chip technology provides a valuable solution to these issues with modular complexity, recapitalizing tissues in 3D to more closely resemble in vivo conditions, and the ability to perform high throughput screens.
This webinar is part of a series where we discuss organ on-a-chip-technology in intestinal drug discovery. In the first webinar, you learned how to develop and assess the physiological relevance of an intestine-on-a-chip model. In this webinar, Claudia Beaurivage, Scientist at Galapagos, will discuss the advantages of organ-on-a-chip technology and how these can be utilized in drug development against IBD.
For this research, two models of increasing physiological relevance were developed from standardized cell lines or patient material. With the use of these models, cytokine release was assessed in response to several compounds to stimulate or inhibit tissue inflammation. These models showed to be successful in determining the efficacy of drug compounds in a cell-type-specific manner.
Join our speaker Claudia Beaurivage, Scientist at Galapagos, to learn everything about:
- The advantages of organ-on-a-chip technology over other techniques to study inflammatory bowel disease
- How organ-on-a-chip model can be applied in drug development
- How to improve the physiological relevance of your organ-on-a-chip model with patient-derived cells